STOCK TITAN

Tenet Reports Strong Third Quarter 2024 Results; Raises 2024 Financial Outlook

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Tenet Healthcare (NYSE: THC) reported strong Q3 2024 results with net income of $472 million ($4.89 per diluted share), including a $209 million after-tax gain from hospital divestitures. Consolidated Adjusted EBITDA reached $978 million, up 14.5% year-over-year. The company's Ambulatory Care segment showed impressive growth with Adjusted EBITDA of $439 million, increasing 18.6%. Based on strong performance, Tenet raised its FY 2024 Adjusted EBITDA outlook to $3.9-4.0 billion, a $50 million increase. The company demonstrated robust cash flow generation with $2.378 billion from operating activities for the first nine months of 2024.

Tenet Healthcare (NYSE: THC) ha riportato risultati solidi per il terzo trimestre del 2024, con un reddito netto di $472 milioni ($4,89 per azione diluita), inclusa una plusvalenza dopo le tasse di $209 milioni derivante dalla dismissione di ospedali. Il Consolidated Adjusted EBITDA ha raggiunto $978 milioni, in aumento del 14,5% rispetto all'anno precedente. Il segmento di Cure Ambulatoriali dell'azienda ha mostrato una crescita impressionante con un Adjusted EBITDA di $439 milioni, in aumento del 18,6%. Sulla base delle forti performance, Tenet ha aumentato la sua previsione di Adjusted EBITDA per l'anno fiscale 2024 a $3,9-4,0 miliardi, con un incremento di $50 milioni. L'azienda ha dimostrato una robusta generazione di flusso di cassa con $2,378 miliardi provenienti dalle attività operative nei primi nove mesi del 2024.

Tenet Healthcare (NYSE: THC) reportó resultados fuertes para el tercer trimestre de 2024 con un ingreso neto de $472 millones ($4.89 por acción diluida), incluyendo una ganancia después de impuestos de $209 millones por la desinversión de hospitales. El EBITDA Ajustado Consolidado alcanzó $978 millones, un aumento del 14.5% interanual. El segmento de Atención Ambulatoria de la compañía mostró un crecimiento impresionante con un EBITDA Ajustado de $439 millones, incrementándose en un 18.6%. Basado en un desempeño sólido, Tenet elevó su perspectiva de EBITDA Ajustado para el año fiscal 2024 a $3.9-4.0 mil millones, un aumento de $50 millones. La compañía demostró una generación de flujo de efectivo robusta con $2.378 mil millones provenientes de actividades operativas durante los primeros nueve meses de 2024.

테넷 헬스케어 (NYSE: THC)는 2024년 3분기 강력한 실적을 발표했으며, 순이익은 4억 7천2백만 달러($4.89 희석된 주당 순이익)입니다. 여기에는 병원 매각으로 인한 세후 2억 9백만 달러의 이익이 포함됩니다. 조정된 EBITDA는 9억 7천8백만 달러에 도달했으며, 전년 대비 14.5% 증가했습니다. 회사의 외래 진료 부문은 4억 3천9백만 달러의 조정된 EBITDA로 18.6% 증가하며 인상적인 성장을 보여주었습니다. 강력한 성과에 기반하여 테넷은 2024 회계연도의 조정된 EBITDA 전망을 39억에서 40억 달러로 상향 조정했으며, 이는 5천만 달러의 증가입니다. 회사는 2024년 첫 9개월 동안 운영 활동으로부터 23억 7천8백만 달러의 견고한 현금 흐름을 생성했습니다.

Tenet Healthcare (NYSE: THC) a annoncé de solides résultats pour le troisième trimestre 2024, avec un revenu net de 472 millions de dollars (4,89 dollars par action diluée), y compris un gain après impôts de 209 millions de dollars provenant de la cession d'hôpitaux. Le EBITDA Ajusté Consolidé a atteint 978 millions de dollars, en hausse de 14,5 % par rapport à l'année précédente. Le segment des Soins Ambulatoires de l'entreprise a montré une croissance impressionnante avec un EBITDA Ajusté de 439 millions de dollars, en augmentation de 18,6 %. Sur la base de ces performances solides, Tenet a relevé ses prévisions d'EBITDA Ajusté pour l'exercice 2024 à 3,9-4,0 milliards de dollars, soit une augmentation de 50 millions de dollars. L'entreprise a également démontré une génération robuste de flux de trésorerie avec 2,378 milliards de dollars provenant des activités opérationnelles pour les neuf premiers mois de 2024.

Tenet Healthcare (NYSE: THC) meldete im dritten Quartal 2024 starke Ergebnisse mit einem Nettogewinn von 472 Millionen Dollar (4,89 Dollar pro verwässerter Aktie), einschließlich eines nach Steuern erzielten Gewinns von 209 Millionen Dollar aus Krankenhausverkäufen. Das konsolidierte Adjusted EBITDA erreichte 978 Millionen Dollar, was einem Anstieg von 14,5 % im Jahresvergleich entspricht. Das Segment der Ambulanten Versorgung des Unternehmens zeigte beeindruckendes Wachstum mit einem Adjusted EBITDA von 439 Millionen Dollar, was 18,6 % mehr entspricht. Aufgrund der starken Leistung hob Tenet seine Prognose für das Adjusted EBITDA im Geschäftsjahr 2024 auf 3,9-4,0 Milliarden Dollar an, was einem Anstieg von 50 Millionen Dollar entspricht. Das Unternehmen wies eine robuste Cashflow-Generierung mit 2,378 Milliarden Dollar aus operativen Tätigkeiten in den ersten neun Monaten des Jahres 2024 aus.

Positive
  • Adjusted EBITDA increased 14.5% to $978 million in Q3 2024
  • Ambulatory Care segment Adjusted EBITDA grew 18.6% to $439 million
  • Same-hospital admissions increased 5.2% year-over-year
  • Operating cash flows improved to $2.378 billion for nine months of 2024
  • Net debt to Adjusted EBITDA ratio improved to 2.22x from 3.89x at year-end 2023
  • Raised FY 2024 Adjusted EBITDA guidance by $50 million
Negative
  • Hospital segment revenues declined 3.4% due to facility divestitures
  • Emergency Room visits decreased 0.2% year-over-year
  • Same-facility surgical cases declined 0.6% on same-business day basis

Insights

Tenet Healthcare delivered an exceptionally strong Q3 2024 with significant financial improvements. Net income surged to $472 million ($4.89 per share), including a $209 million gain from divestitures. Key highlights include:

  • Adjusted EBITDA grew 14.5% to $978 million
  • Ambulatory Care segment showed impressive 18.6% EBITDA growth
  • Strong cash flow with $2.378 billion from operations
  • Reduced leverage ratio to 2.22x from 3.89x

The company's strategic divestitures and focus on high-margin ambulatory services are paying off. The raised FY2024 outlook and robust free cash flow generation demonstrate strong operational execution and improving financial health.

The operational metrics reveal strong fundamental performance across both hospital and ambulatory segments. Notable trends include:

  • Same-hospital admissions up 5.2%, showing strong patient demand
  • Ambulatory surgical case revenue per case increased 7.6%
  • Improved payer mix and higher acuity services driving better margins

The strategic transformation through hospital divestitures while expanding the ambulatory platform positions Tenet for sustained growth. The focus on higher-margin services and operational efficiency is evident in the improving EBITDA margins, particularly in the hospital segment which rose to 13.5%.

  • Net income available to common shareholders in third quarter 2024 was $472 million, or $4.89 per diluted share, including an after-tax gain of $209 million, or $2.16 per diluted share, primarily associated with previously announced hospital divestitures
  • Adjusted diluted earnings per share1 was $2.93 in third quarter 2024
  • Consolidated Adjusted EBITDA1 in third quarter 2024 of $978 million increased 14.5% over third quarter 2023
  • Third quarter 2024 Ambulatory Care Adjusted EBITDA of $439 million increased 18.6% over third quarter 2023
  • FY 2024 Adjusted EBITDA Outlook now expected to be in the range of $3.9 billion to $4.0 billion, a $50 million increase

DALLAS--(BUSINESS WIRE)-- Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2024.

"Our businesses continue to produce strong results and generate robust free cash flow with same store revenue growth and profitability well above our expectations due to the focused execution of our strategy and disciplined operations," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We have furthered our portfolio transformation and are well-positioned to deliver enhanced value to our patients, physician partners, and shareholders."

Tenet’s results for third quarter 2024 versus third quarter 2023 are as follows:

 

Three Months Ended
September 30,

Nine Months Ended
September 30,

($ in millions, except per share results)

2024

2023

2024

2023

Net operating revenues

$5,122

$5,066

$15,593

$15,169

Net income available to Tenet common shareholders

$472

$101

$2,882

$367

Net income available to Tenet common shareholders per diluted share

$4.89

$0.94

$29.27

$3.41

Adjusted EBITDA1

$978

$854

$2,947

$2,529

Adjusted diluted earnings per share1

$2.93

$1.44

$8.47

$4.30

  • Net income available to the Company’s common shareholders in the third quarter 2024 was $472 million, or $4.89 per diluted share, versus $101 million, or $0.94 per diluted share, in third quarter 2023. Third quarter 2024 results included a pre-tax gain of $348 million ($209 million after-tax or $2.16 per diluted share) primarily associated with the sale of the Company's 70% majority ownership interest in Brookwood Baptist Health in Alabama.
  • Adjusted EBITDA1 in third quarter 2024 was $978 million compared to $854 million in third quarter 2023, reflecting strong same-hospital admissions growth, strong ambulatory net revenue per case growth, favorable payer mix, and increased Medicaid supplemental revenues in Michigan, partially offset by higher medical fees as well as the impact of hospital divestitures.

Balance Sheet and Cash Flows

  • Cash flows provided by operating activities for the nine months ended September 30, 2024 were $2.378 billion versus $1.550 billion for the nine months ended September 30, 2023.
  • The Company produced free cash flow1 of $1.777 billion for the nine months ended September 30, 2024 versus $1.007 billion for the nine months ended September 30, 2023.
  • In the three months ended September 30, 2024, the Company repurchased 795,112 shares of common stock for $124 million. In the nine months ended September 30, 2024, the Company repurchased 5,596,573 shares of common stock for $672 million.
  • The Company’s ratio of net debt to Adjusted EBITDA1 was 2.22x at September 30, 2024 compared to 2.61x at June 30, 2024 and 3.89x at December 31, 2023.

Recent Transaction

  • On October 1, 2024, the Company announced the completion of the sale of its 70% majority ownership interest in Brookwood Baptist Health in Birmingham, Alabama to Orlando Health in the third quarter of 2024. The completed transaction included five hospitals and other related operations. Our outlook for full year 2024 net cash provided by operating activities and free cash flow1 now reflects the anticipated payment of approximately $175 million of income taxes, primarily in connection with the net gain on the sale of these facilities.

Ambulatory Care (Ambulatory) Segment

Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of September 30, 2024, USPI had interests in 520 ambulatory surgery centers (376 consolidated) and 24 surgical hospitals (seven consolidated) in 37 states.

 

Three Months Ended
September 30,

Nine Months Ended
September 30,

Ambulatory segment results ($ in millions)

2024

2023

2024

2023

Revenues

 

 

 

 

Net operating revenues

$1,139

$941

$3,275

$2,788

Same-facility system-wide net patient service revenues2

$1,895

$1,744

$5,516

$5,133

Volume Changes versus the Prior-Year Period

 

 

 

 

Same-facility system-wide surgical cases2

1.0 %

4.1 %

0.4 %

6.2 %

Same-facility system-wide surgical cases on same-business day basis2

(0.6) %

5.8 %

(0.1) %

6.8 %

Adjusted EBITDA, Margins and NCI

 

 

 

 

Adjusted EBITDA

$439

$370

$1,280

$1,080

Adjusted EBITDA margin

38.5%

39.3%

39.1%

38.7%

Adjusted EBITDA less NCI

$265

$233

$779

$678

  • Third quarter 2024 net operating revenues increased 21.0% compared to third quarter 2023 driven by strong net revenue per case growth, acquisitions of facilities, and increased service lines.
  • Surgical business same-facility system-wide net patient service revenues increased 8.7% in third quarter 2024 compared to third quarter 2023, with cases up 1.0% and net revenue per case up 7.6%. Net revenue per case growth was driven by higher acuity associated with favorable case mix as well as favorable payer mix.
  • Third quarter 2024 Adjusted EBITDA increased 18.6% compared to third quarter 2023, due to strong net revenue per case growth, disciplined expense management, and contributions from acquisitions and de novo facilities.

Hospital Operations and Services (Hospital) Segment

Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.

 

Three Months Ended
September 30,

Nine Months Ended
September 30,

Hospital segment results ($ in millions)

2024

2023

2024

2023

Revenues

 

 

 

 

Net operating revenues

$3,983

$4,125

$12,318

$12,381

Same-hospital net patient service revenues3

$3,383

$3,190

$10,298

$9,507

Same-Hospital Volume Changes versus the Prior-Year Period

 

 

 

 

Admissions

5.2%

0.6%

4.9%

2.6%

Adjusted admissions4

2.7%

0.4%

2.3%

3.3%

Outpatient visits (including outpatient ER visits)

0.5%

(2.0)%

0.1%

(1.0)%

Emergency Room visits (inpatient and outpatient)

(0.2)%

(0.9)%

1.8%

1.3%

Hospital surgeries

0.6%

(0.7)%

—%

0.5%

Adjusted EBITDA

 

 

 

 

Adjusted EBITDA

$539

$484

$1,667

$1,449

Adjusted EBITDA margin

13.5%

11.7%

13.5%

11.7%

  • Third quarter 2024 net operating revenues declined 3.4% from third quarter 2023 primarily due to the impact of hospital divestitures in first quarter 2024, partially offset by strong same hospital admissions growth, favorable payer mix, and improved pricing yield.
  • Same-hospital net patient service revenue per adjusted admission increased 3.3% year-over-year for third quarter 2024 primarily due to improved pricing yield, favorable payer mix, and our focus on growing higher acuity services.
  • Adjusted EBITDA in third quarter 2024 was $539 million compared to $484 million in third quarter 2023, reflecting strong same-hospital admissions growth and revenue per adjusted admission, favorable payer mix, and increased supplemental revenues in Michigan, partially offset by higher medical fees as well as the impact of hospital divestitures.

2024 Outlook1

Tenet’s Outlook for full year 2024 (consolidated and by segment) and fourth quarter 2024 follows. This outlook reflects the sale of three Coastal South Carolina hospitals on January 31, 2024, the sale of six California hospitals on March 31, 2024, and the sale of five Alabama hospitals on September 30, 2024.

CONSOLIDATED ($ in millions, except per share amounts)

FY 2024 Outlook

Fourth Quarter
2024 Outlook

Net operating revenues

$20,600 to $20,800

$5,007 to $5,207

Net income available to Tenet common stockholders

$3,093 to $3,193

$211 to $311

Adjusted EBITDA

$3,900 to $4,000

$953 to $1,053

Adjusted EBITDA margin

18.9% to 19.2%

19.0% to 20.2%

Diluted income per common share

$31.56 to $32.58

$2.20 to $3.24

Adjusted net income

$1,090 to $1,150

$258 to $318

Adjusted diluted earnings per share

$11.12 to $11.73

$2.69 to $3.31

Equity in earnings of unconsolidated affiliates

$260 to $270

$78 to $88

Depreciation and amortization

$820 to $840

$195 to $215

Interest expense

$820 to $830

$197 to $207

Income tax expense5

$1,185 to $1,215

$84 to $114

Net income available to NCI

$835 to $855

$225 to $245

Weighted average diluted common shares

~98 million

~96 million

NCI cash distributions

$725 to $775

 

Net cash provided by operating activities6

$1,775 to $2,125

 

Adjusted net cash provided by operating activities6

$1,950 to $2,250

 

Capital expenditures

$800 to $900

 

Free cash flow6

$975 to $1,225

 

Adjusted free cash flow6

$1,150 to $1,350

 

 

Ambulatory Segment ($ in millions)

FY 2024 Outlook

Net operating revenues

$4,375 to $4,425

Adjusted EBITDA

$1,760 to $1,800

NCI

$690 to $710

Adjusted EBITDA less NCI

$1,070 to $1,090

Changes versus prior year7:

 

Surgical cases volumes

Up 0.0% to 1.0%

Net revenues per surgical case

Up 6.0% to 7.0%

Hospital Segment ($ in millions)

FY 2024 Outlook

Net operating revenues

$16,225 to $16,375

Adjusted EBITDA

$2,140 to $2,200

NCI

$145 to $145

Changes versus prior year7:

 

Inpatient admissions

Up 4.0% to 5.0%

Adjusted admissions

Up 1.5% to 2.5%

Management’s Webcast Discussion of Results

Tenet management will discuss the Company’s third quarter 2024 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on October 29, 2024. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.

The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on October 29, 2024.

Cautionary Statement

This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2023 and other filings with the Securities and Exchange Commission.

Footnotes

  1. Tables and discussions throughout this earnings release include certain financial measures, including those related to our fourth quarter and full year 2024 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.
  2. Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.
  3. For 2024, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2023 through September 30, 2024. Amounts associated with physician practices are excluded.
  4. Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.
  5. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less GAAP facility level NCI expense plus permanent differences, and non-deductible interest expense.
  6. For 2024, Outlook for net cash provided by operating activities, Adjusted net cash provided by operating activities, Free cash flow and Adjusted free cash flow include an estimate of approximately $875 million of net income tax payments associated with the gains on sale of the three hospitals and related operations in South Carolina, the six hospitals and related operations in California, and the five hospitals and related operations in Alabama, approximately $175 million of which have already been paid as of September 30, 2024.
  7. Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Non-GAAP Financial Measures

The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

  • Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
  • Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment.
  • Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.
  • Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.

Tenet Healthcare Corporation

Financial Statements and Reconciliations

Third Quarter Earnings Release

 

Table of Contents

Description

Page

Consolidated Statements of Operations

12

Consolidated Balance Sheets

14

Consolidated Statements of Cash Flows

15

Segment Reporting

17

Table #1 – Reconciliations of Net Income to Adjusted Net Income

18

Table #2 – Reconciliations of Net Income to Adjusted EBITDA

19

Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

20

Table #4 – Reconciliations of Outlook Net Income to Outlook Adjusted Net Income

21

Table #5 – Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA

22

Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

23

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

(Dollars in millions, except per share amounts)

 

Three Months Ended September 30,

 

2024

 

%

 

2023

 

%

 

Change

Net operating revenues

 

$

5,122

 

 

100.0

%

 

$

5,066

 

 

100.0

%

 

1.1

%

Grant income

 

 

4

 

 

0.1

%

 

 

3

 

 

0.1

%

 

33.3

%

Equity in earnings of unconsolidated affiliates

 

 

62

 

 

1.2

%

 

 

51

 

 

1.0

%

 

21.6

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

2,218

 

 

43.3

%

 

 

2,288

 

 

45.2

%

 

(3.1

)%

Supplies

 

 

881

 

 

17.2

%

 

 

877

 

 

17.3

%

 

0.5

%

Other operating expenses, net

 

 

1,111

 

 

21.6

%

 

 

1,101

 

 

21.7

%

 

0.9

%

Depreciation and amortization

 

 

209

 

 

4.1

%

 

 

224

 

 

4.5

%

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

19

 

 

0.4

%

 

 

47

 

 

0.9

%

 

 

Litigation and investigation costs

 

 

9

 

 

0.2

%

 

 

14

 

 

0.3

%

 

 

Net losses (gains) on sales, consolidation and deconsolidation of facilities

 

 

(348

)

 

(6.8

)%

 

 

1

 

 

%

 

 

Operating income

 

 

1,089

 

 

21.3

%

 

 

568

 

 

11.2

%

 

 

Interest expense

 

 

(202

)

 

 

 

 

(227

)

 

 

 

 

Other non-operating income, net

 

 

35

 

 

 

 

 

4

 

 

 

 

 

Income before income taxes

 

 

922

 

 

 

 

 

345

 

 

 

 

 

Income tax expense

 

 

(241

)

 

 

 

 

(79

)

 

 

 

 

Net income

 

 

681

 

 

 

 

 

266

 

 

 

 

 

Less: Net income available to noncontrolling interests

 

 

209

 

 

 

 

 

165

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

472

 

 

 

 

$

101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share available to Tenet Healthcare Corporation common shareholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

$

4.93

 

 

 

 

$

0.99

 

 

 

 

 

Diluted

 

$

4.89

 

 

 

 

$

0.94

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares and dilutive securities outstanding (in thousands):

 

 

 

 

 

 

 

 

 

 

Basic

 

 

95,665

 

 

 

 

 

101,544

 

 

 

 

 

Diluted

 

 

96,652

 

 

 

 

 

104,425

 

 

 

 

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

(Dollars in millions, except per share amounts)

 

Nine Months Ended September 30,

 

2024

 

%

 

2023

 

%

 

Change

Net operating revenues

 

$

15,593

 

 

100.0

%

 

$

15,169

 

 

100.0

%

 

2.8

%

Grant income

 

 

9

 

 

0.1

%

 

 

14

 

 

0.1

%

 

(35.7

)%

Equity in earnings of unconsolidated affiliates

 

 

182

 

 

1.2

%

 

 

155

 

 

1.0

%

 

17.4

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

6,707

 

 

43.0

%

 

 

6,831

 

 

45.0

%

 

(1.8

)%

Supplies

 

 

2,717

 

 

17.4

%

 

 

2,659

 

 

17.5

%

 

2.2

%

Other operating expenses, net

 

 

3,413

 

 

22.0

%

 

 

3,319

 

 

21.9

%

 

2.8

%

Depreciation and amortization

 

 

625

 

 

4.0

%

 

 

654

 

 

4.3

%

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

75

 

 

0.5

%

 

 

84

 

 

0.6

%

 

 

Litigation and investigation costs

 

 

18

 

 

0.1

%

 

 

28

 

 

0.2

%

 

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

(2,906

)

 

(18.6

)%

 

 

(12

)

 

(0.1

)%

 

 

Operating income

 

 

5,135

 

 

32.9

%

 

 

1,775

 

 

11.7

%

 

 

Interest expense

 

 

(623

)

 

 

 

 

(674

)

 

 

 

 

Other non-operating income, net

 

 

89

 

 

 

 

 

8

 

 

 

 

 

Loss from early extinguishment of debt

 

 

(8

)

 

 

 

 

(11

)

 

 

 

 

Income before income taxes

 

 

4,593

 

 

 

 

 

1,098

 

 

 

 

 

Income tax expense

 

 

(1,101

)

 

 

 

 

(243

)

 

 

 

 

Net income

 

 

3,492

 

 

 

 

 

855

 

 

 

 

 

Less: Net income available to noncontrolling interests

 

 

610

 

 

 

 

 

488

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

2,882

 

 

 

 

$

367

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share available to Tenet Healthcare Corporation common shareholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

$

29.56

 

 

 

 

$

3.60

 

 

 

 

 

Diluted

 

$

29.27

 

 

 

 

$

3.41

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares and dilutive securities outstanding (in thousands):

 

 

 

 

 

 

 

 

 

 

Basic

 

 

97,505

 

 

 

 

 

101,869

 

 

 

 

 

Diluted

 

 

98,518

 

 

 

 

 

105,021

 

 

 

 

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

(Dollars in millions)

 

September 30,

 

December 31,

 

2024

 

2023

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

4,094

 

 

$

1,228

 

Accounts receivable

 

 

2,598

 

 

 

2,914

 

Inventories of supplies, at cost

 

 

356

 

 

 

411

 

Assets held for sale

 

 

20

 

 

 

775

 

Other current assets

 

 

1,691

 

 

 

1,839

 

Total current assets

 

 

8,759

 

 

 

7,167

 

Investments and other assets

 

 

3,064

 

 

 

3,157

 

Deferred income taxes

 

 

36

 

 

 

77

 

Property and equipment, at cost, less accumulated depreciation and amortization

 

 

5,552

 

 

 

6,236

 

Goodwill

 

 

10,588

 

 

 

10,307

 

Other intangible assets, at cost, less accumulated amortization

 

 

1,373

 

 

 

1,368

 

Total assets

 

$

29,372

 

 

$

28,312

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Current portion of long-term debt

 

$

95

 

 

$

120

 

Accounts payable

 

 

1,265

 

 

 

1,408

 

Accrued compensation and benefits

 

 

879

 

 

 

930

 

Professional and general liability reserves

 

 

286

 

 

 

254

 

Accrued interest payable

 

 

248

 

 

 

200

 

Liabilities held for sale

 

 

12

 

 

 

69

 

Income tax payable

 

 

826

 

 

 

23

 

Other current liabilities

 

 

1,927

 

 

 

1,756

 

Total current liabilities

 

 

5,538

 

 

 

4,760

 

Long-term debt, net of current portion

 

 

12,776

 

 

 

14,882

 

Professional and general liability reserves

 

 

855

 

 

 

792

 

Defined benefit plan obligations

 

 

308

 

 

 

335

 

Deferred income taxes

 

 

260

 

 

 

326

 

Other long-term liabilities

 

 

1,560

 

 

 

1,709

 

Total liabilities

 

 

21,297

 

 

 

22,804

 

Commitments and contingencies

 

 

 

 

Redeemable noncontrolling interests in equity of consolidated subsidiaries

 

 

2,649

 

 

 

2,391

 

Equity:

 

 

 

 

Shareholders’ equity:

 

 

 

 

Common stock

 

 

8

 

 

 

8

 

Additional paid-in capital

 

 

4,849

 

 

 

4,834

 

Accumulated other comprehensive loss

 

 

(175

)

 

 

(181

)

Retained earnings (accumulated deficit)

 

 

2,690

 

 

 

(192

)

Common stock in treasury, at cost

 

 

(3,538

)

 

 

(2,861

)

Total shareholders’ equity

 

 

3,834

 

 

 

1,608

 

Noncontrolling interests

 

 

1,592

 

 

 

1,509

 

Total equity

 

 

5,426

 

 

 

3,117

 

Total liabilities and equity

 

$

29,372

 

 

$

28,312

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

(Dollars in millions)

 

Nine Months Ended

 

September 30,

 

2024

 

2023

Net income

 

$

3,492

 

 

$

855

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

625

 

 

 

654

 

Deferred income tax expense (benefit)

 

 

(29

)

 

 

75

 

Stock-based compensation expense

 

 

52

 

 

 

48

 

Impairment and restructuring charges, and acquisition-related costs

 

 

75

 

 

 

84

 

Litigation and investigation costs

 

 

18

 

 

 

28

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

(2,906

)

 

 

(12

)

Loss from early extinguishment of debt

 

 

8

 

 

 

11

 

Equity in earnings of unconsolidated affiliates, net of distributions received

 

 

(9

)

 

 

5

 

Amortization of debt discount and debt issuance costs

 

 

21

 

 

 

25

 

Net gains from the sale of investments and long-lived assets

 

 

(2

)

 

 

(25

)

Other items, net

 

 

(3

)

 

 

(1

)

Changes in cash from operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 

183

 

 

 

31

 

Inventories and other current assets

 

 

10

 

 

 

(49

)

Income taxes

 

 

821

 

 

 

(46

)

Accounts payable, accrued expenses and other current liabilities

 

 

123

 

 

 

(38

)

Other long-term liabilities

 

 

18

 

 

 

10

 

Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(119

)

 

 

(105

)

Net cash provided by operating activities

 

 

2,378

 

 

 

1,550

 

Cash flows from investing activities:

 

 

 

 

Purchases of property and equipment

 

 

(601

)

 

 

(543

)

Purchases of businesses or joint venture interests, net of cash acquired

 

 

(524

)

 

 

(110

)

Proceeds from sales of facilities and other assets

 

 

4,965

 

 

 

38

 

Proceeds from sales of marketable securities and long-term investments

 

 

25

 

 

 

40

 

Purchases of marketable securities and long-term investments

 

 

(46

)

 

 

(54

)

Other items, net

 

 

(18

)

 

 

(7

)

Net cash provided by (used in) investing activities

 

 

3,801

 

 

 

(636

)

Cash flows from financing activities:

 

 

 

 

Repayments of borrowings

 

 

(2,212

)

 

 

(1,478

)

Proceeds from borrowings

 

 

16

 

 

 

1,368

 

Repurchases of common stock

 

 

(672

)

 

 

(90

)

Debt issuance costs

 

 

 

 

 

(16

)

Distributions paid to noncontrolling interests

 

 

(496

)

 

 

(425

)

Proceeds from the sale of noncontrolling interests

 

 

13

 

 

 

37

 

Purchases of noncontrolling interests

 

 

(127

)

 

 

(127

)

Advances from managed care payers

 

 

342

 

 

 

 

Repayments of advances from managed care payers

 

 

(160

)

 

 

 

Other items, net

 

 

(17

)

 

 

13

 

Net cash used in financing activities

 

 

(3,313

)

 

 

(718

)

Net increase in cash and cash equivalents

 

 

2,866

 

 

 

196

 

Cash and cash equivalents at beginning of period

 

 

1,228

 

 

 

858

 

Cash and cash equivalents at end of period

 

$

4,094

 

 

$

1,054

 

Supplemental disclosures:

 

 

 

 

Interest paid, net of capitalized interest

 

$

(555

)

 

$

(589

)

Income tax payments, net

 

$

(308

)

 

$

(212

)

TENET HEALTHCARE CORPORATION

SEGMENT REPORTING

(Unaudited)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(Dollars in millions)

 

2024

 

2023

 

2024

 

2023

Net operating revenues:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

1,139

 

 

$

941

 

 

$

3,275

 

 

$

2,788

 

Hospital Operations and Services

 

 

3,983

 

 

 

4,125

 

 

 

12,318

 

 

 

12,381

 

Total

 

$

5,122

 

 

$

5,066

 

 

$

15,593

 

 

$

15,169

 

 

 

 

 

 

 

 

 

 

Equity in earnings of unconsolidated affiliates:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

61

 

 

$

50

 

 

$

175

 

 

$

149

 

Hospital Operations and Services

 

 

1

 

 

 

1

 

 

 

7

 

 

 

6

 

Total

 

$

62

 

 

$

51

 

 

$

182

 

 

$

155

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

439

 

 

$

370

 

 

$

1,280

 

 

$

1,080

 

Hospital Operations and Services

 

 

539

 

 

 

484

 

 

 

1,667

 

 

 

1,449

 

Total

 

$

978

 

 

$

854

 

 

$

2,947

 

 

$

2,529

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins:

 

 

 

 

 

 

 

 

Ambulatory Care

 

 

38.5

%

 

 

39.3

%

 

 

39.1

%

 

 

38.7

%

Hospital Operations and Services

 

 

13.5

%

 

 

11.7

%

 

 

13.5

%

 

 

11.7

%

Total

 

 

19.1

%

 

 

16.9

%

 

 

18.9

%

 

 

16.7

%

 

 

 

 

 

 

 

 

 

Capital expenditures:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

28

 

 

$

20

 

 

$

65

 

 

$

58

 

Hospital Operations and Services

 

 

188

 

 

 

156

 

 

 

536

 

 

 

485

 

Total

 

$

216

 

 

$

176

 

 

$

601

 

 

$

543

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common

Shareholders to Adjusted Net Income Available to Common Shareholders

(Unaudited)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(Dollars in millions, except per share amounts)

 

2024

 

2023

 

2024

 

2023

Net income available to Tenet Healthcare Corporation common shareholders

 

$

472

 

 

$

101

 

 

$

2,882

 

 

$

367

 

Less:

 

 

 

 

 

 

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

(19

)

 

 

(47

)

 

 

(75

)

 

 

(84

)

Litigation and investigation costs

 

 

(9

)

 

 

(14

)

 

 

(18

)

 

 

(28

)

Net gains (losses) on sales, consolidation and deconsolidation of facilities

 

 

348

 

 

 

(1

)

 

 

2,906

 

 

 

12

 

Loss from early extinguishment of debt

 

 

 

 

 

 

 

 

(8

)

 

 

(11

)

Tax and noncontrolling interests impact of above items

 

 

(130

)

 

 

10

 

 

 

(755

)

 

 

17

 

Adjusted net income available to common shareholders

 

$

282

 

 

$

153

 

 

$

832

 

 

$

461

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share

 

$

4.89

 

 

$

0.94

 

 

$

29.27

 

 

$

3.41

 

Less:

 

 

 

 

 

 

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

(0.20

)

 

 

(0.45

)

 

 

(0.76

)

 

 

(0.80

)

Litigation and investigation costs

 

 

(0.09

)

 

 

(0.13

)

 

 

(0.19

)

 

 

(0.27

)

Net gains (losses) on sales, consolidation and deconsolidation of facilities

 

 

3.60

 

 

 

(0.01

)

 

 

29.50

 

 

 

0.12

 

Loss from early extinguishment of debt

 

 

 

 

 

 

 

 

(0.08

)

 

 

(0.10

)

Tax and noncontrolling interests impact of above items

 

 

(1.35

)

 

 

0.09

 

 

 

(7.67

)

 

 

0.16

 

Adjusted diluted earnings per share

 

$

2.93

 

 

$

1.44

 

 

$

8.47

 

 

$

4.30

 

 

 

 

 

 

 

 

 

 

Weighted average basic shares outstanding (in thousands)

 

 

95,665

 

 

 

101,544

 

 

 

97,505

 

 

 

101,869

 

Weighted average dilutive shares outstanding (in thousands)

 

 

96,652

 

 

 

104,425

 

 

 

98,518

 

 

 

105,021

 

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common

Shareholders to Adjusted EBITDA

(Unaudited)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(Dollars in millions)

 

2024

 

2023

 

2024

 

2023

Net income available to Tenet Healthcare Corporation common shareholders

 

$

472

 

 

$

101

 

 

$

2,882

 

 

$

367

 

Less:

 

 

 

 

 

 

 

 

Net income available to noncontrolling interests

 

 

(209

)

 

 

(165

)

 

 

(610

)

 

 

(488

)

Net income

 

 

681

 

 

 

266

 

 

 

3,492

 

 

 

855

 

Income tax expense

 

 

(241

)

 

 

(79

)

 

 

(1,101

)

 

 

(243

)

Loss from early extinguishment of debt

 

 

 

 

 

 

 

 

(8

)

 

 

(11

)

Other non-operating income, net

 

 

35

 

 

 

4

 

 

 

89

 

 

 

8

 

Interest expense

 

 

(202

)

 

 

(227

)

 

 

(623

)

 

 

(674

)

Operating income

 

 

1,089

 

 

 

568

 

 

 

5,135

 

 

 

1,775

 

Litigation and investigation costs

 

 

(9

)

 

 

(14

)

 

 

(18

)

 

 

(28

)

Net gains (losses) on sales, consolidation and deconsolidation of facilities

 

 

348

 

 

 

(1

)

 

 

2,906

 

 

 

12

 

Impairment and restructuring charges, and acquisition-related costs

 

 

(19

)

 

 

(47

)

 

 

(75

)

 

 

(84

)

Depreciation and amortization

 

 

(209

)

 

 

(224

)

 

 

(625

)

 

 

(654

)

Adjusted EBITDA

 

$

978

 

 

$

854

 

 

$

2,947

 

 

$

2,529

 

 

 

 

 

 

 

 

 

 

Net operating revenues

 

$

5,122

 

 

$

5,066

 

 

$

15,593

 

 

$

15,169

 

 

 

 

 

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues

 

 

9.2

%

 

 

2.0

%

 

 

18.5

%

 

 

2.4

%

 

 

 

 

 

 

 

 

 

Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)

 

 

19.1

%

 

 

16.9

%

 

 

18.9

%

 

 

16.7

%

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #3 – Reconciliations of Net Cash Provided by Operating Activities to

Free Cash Flow and Adjusted Free Cash Flow

(Unaudited)

 

 

 

2024

(Dollars in millions)

 

Q3

 

YTD

Net cash provided by operating activities

 

$

1,045

 

 

$

2,378

 

Purchases of property and equipment

 

 

(216

)

 

 

(601

)

Free cash flow

 

$

829

 

 

$

1,777

 

 

 

 

 

 

Net cash provided by investing activities

 

$

667

 

 

$

3,801

 

Net cash used in financing activities

 

$

(498

)

 

$

(3,313

)

 

 

 

 

 

Net cash provided by operating activities

 

$

1,045

 

 

$

2,378

 

Less:

 

 

 

 

Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(55

)

 

 

(119

)

Adjusted net cash provided by operating activities

 

 

1,100

 

 

 

2,497

 

Purchases of property and equipment

 

 

(216

)

 

 

(601

)

Adjusted free cash flow

 

$

884

 

 

$

1,896

 

 

 

2023

(Dollars in millions)

 

Q3

 

YTD

Net cash provided by operating activities

 

$

503

 

 

$

1,550

 

Purchases of property and equipment

 

 

(176

)

 

 

(543

)

Free cash flow

 

$

327

 

 

$

1,007

 

 

 

 

 

 

Net cash used in investing activities

 

$

(169

)

 

$

(636

)

Net cash used in financing activities

 

$

(214

)

 

$

(718

)

 

 

 

 

 

Net cash provided by operating activities

 

$

503

 

 

$

1,550

 

Less:

 

 

 

 

Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(27

)

 

 

(105

)

Adjusted net cash provided by operating activities

 

 

530

 

 

 

1,655

 

Purchases of property and equipment

 

 

(176

)

 

 

(543

)

Adjusted free cash flow

 

$

354

 

 

$

1,112

 

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common

Shareholders to Outlook Adjusted Net Income Available to Common Shareholders

(Unaudited)

 

 

 

Fourth Quarter 2024

 

FY 2024

(Dollars in millions, except per share amounts)

 

Low

 

High

 

Low

 

High

Net income available to Tenet Healthcare Corporation common shareholders

 

$

211

 

 

$

311

 

 

$

3,093

 

 

$

3,193

 

Less:

 

 

 

 

 

 

 

 

Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)

 

 

(57

)

 

 

(7

)

 

 

(150

)

 

 

(100

)

Net gains on sales, consolidation and deconsolidation of facilities(2)

 

 

 

 

 

 

 

 

2,906

 

 

 

2,906

 

Loss from early extinguishment of debt(2)

 

 

 

 

 

 

 

 

(8

)

 

 

(8

)

Tax and noncontrolling interests impact of above items

 

 

10

 

 

 

 

 

 

(745

)

 

 

(755

)

Adjusted net income available to common shareholders

 

$

258

 

 

$

318

 

 

$

1,090

 

 

$

1,150

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share

 

$

2.20

 

 

$

3.24

 

 

$

31.56

 

 

$

32.58

 

Less:

 

 

 

 

 

 

 

 

Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(0.59

)

 

 

(0.07

)

 

 

(1.53

)

 

 

(1.02

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

 

 

 

29.65

 

 

 

29.65

 

Loss from early extinguishment of debt

 

 

 

 

 

 

 

 

(0.08

)

 

 

(0.08

)

Tax and noncontrolling interests impact of above items

 

 

0.10

 

 

 

 

 

 

(7.60

)

 

 

(7.70

)

Adjusted diluted earnings per share

 

$

2.69

 

 

$

3.31

 

 

$

11.12

 

 

$

11.73

 

 

 

 

 

 

 

 

 

 

Weighted average basic shares outstanding (in thousands)

 

 

95,000

 

 

 

95,000

 

 

 

97,000

 

 

 

97,000

 

Weighted average dilutive shares outstanding (in thousands)

 

 

96,000

 

 

 

96,000

 

 

 

98,000

 

 

 

98,000

 

(1)

The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

 

(2)

The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2024.

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation

Common Shareholders to Outlook Adjusted EBITDA

(Unaudited)

 

 

 

Fourth Quarter 2024

 

FY 2024

(Dollars in millions)

 

Low

 

High

 

Low

 

High

Net income available to Tenet Healthcare Corporation common shareholders

 

$

211

 

 

$

311

 

 

$

3,093

 

 

$

3,193

 

Less:

 

 

 

 

 

 

 

 

Net income available to noncontrolling interests

 

 

(225

)

 

 

(245

)

 

 

(835

)

 

 

(855

)

Income tax expense

 

 

(84

)

 

 

(114

)

 

 

(1,185

)

 

 

(1,215

)

Interest expense

 

 

(207

)

 

 

(197

)

 

 

(830

)

 

 

(820

)

Loss from early extinguishment of debt(2)

 

 

 

 

 

 

 

 

(8

)

 

 

(8

)

Other non-operating income, net

 

 

26

 

 

 

36

 

 

 

115

 

 

 

125

 

Net gains on sales, consolidation and deconsolidation of facilities(2)

 

 

 

 

 

 

 

 

2,906

 

 

 

2,906

 

Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)

 

 

(57

)

 

 

(7

)

 

 

(150

)

 

 

(100

)

Depreciation and amortization

 

 

(195

)

 

 

(215

)

 

 

(820

)

 

 

(840

)

Adjusted EBITDA

 

$

953

 

 

$

1,053

 

 

$

3,900

 

 

$

4,000

 

 

 

 

 

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

211

 

 

$

311

 

 

$

3,093

 

 

$

3,193

 

Net operating revenues

 

$

5,007

 

 

$

5,207

 

 

$

20,600

 

 

$

20,800

 

Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues

 

 

4.2

%

 

 

6.0

%

 

 

15.0

%

 

 

15.4

%

Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)

 

 

19.0

%

 

 

20.2

%

 

 

18.9

%

 

 

19.2

%

(1)

The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

 

(2)

The Company does not generally forecast net gains on sales, consolidation and deconsolidation of facilities or losses from the early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2024.

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities

to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

(Unaudited)

 

 

 

FY 2024

(Dollars in millions)

 

Low

 

High

Net cash provided by operating activities

 

$

1,775

 

 

$

2,125

 

Purchases of property and equipment

 

 

(800

)

 

 

(900

)

Free cash flow

 

$

975

 

 

$

1,225

 

 

 

 

 

 

Net cash provided by operating activities

 

$

1,775

 

 

$

2,125

 

Less:

 

 

 

 

Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1)

 

 

(175

)

 

 

(125

)

Adjusted net cash provided by operating activities

 

 

1,950

 

 

 

2,250

 

Purchases of property and equipment

 

 

(800

)

 

 

(900

)

Adjusted free cash flow(2)

 

$

1,150

 

 

$

1,350

 

(1)

The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

 

(2)

The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests.

 

Investor Contact

Will McDowell

469-893-2387

william.mcdowell@tenethealth.com

Media Contact

Robert Dyer

469-893-2640

mediarelations@tenethealth.com

Source: Tenet Healthcare Corporation

FAQ

What was Tenet Healthcare's (THC) Q3 2024 earnings per share?

Tenet Healthcare reported Q3 2024 earnings of $4.89 per diluted share, with adjusted diluted earnings per share of $2.93.

How much did Tenet's (THC) Adjusted EBITDA grow in Q3 2024?

Tenet's Consolidated Adjusted EBITDA grew 14.5% to $978 million in Q3 2024 compared to Q3 2023.

What is Tenet Healthcare's (THC) updated EBITDA guidance for 2024?

Tenet raised its FY 2024 Adjusted EBITDA outlook to $3.9-4.0 billion, a $50 million increase from previous guidance.

How many shares did Tenet (THC) repurchase in Q3 2024?

Tenet repurchased 795,112 shares of common stock for $124 million in Q3 2024.

Tenet Healthcare Corporation New

NYSE:THC

THC Rankings

THC Latest News

THC Stock Data

15.14B
97.68M
1.16%
98.55%
2.51%
Medical Care Facilities
Pharmaceutical Preparations
Link
United States of America
CHAPEL HILL